A Phase 2, Open-Label Study to Evaluate Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic Human Papilloma Virus Associated Cancers

Trial Profile

A Phase 2, Open-Label Study to Evaluate Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic Human Papilloma Virus Associated Cancers

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 28 May 2018

At a glance

  • Drugs Durvalumab (Primary) ; MEDI 0457 (Primary)
  • Indications Anal cancer; Cervical cancer; Human papillomavirus infections; Penile cancer; Vulvovaginal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 Jun 2018.
    • 22 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top